A Next-Generation Drug Causes Dramatic Weight Loss, Eli Lilly Says
Eli Lilly has announced positive results for its experimental drug retatrutide, which targets three hormones related to weight loss. In a recent study, participants lost up to 28% of their body weight over 1.5 years, comparable to results from bariatric surgery. The company is conducting further studies to explore the drug's health benefits and compare it with other weight-loss medications.
- ▪Retatrutide helped participants lose up to 28% of their body weight over 1.5 years.
- ▪The drug targets three hormones, unlike current GLP-1 drugs that target one or two.
- ▪About 11% of participants on the highest dose stopped taking retatrutide due to side effects.
Opening excerpt (first ~120 words) tap to expand
Eli Lilly is reporting promising results for the first drug to target three hormones related to weight loss—not just one or two, as current GLP-1 drugs do. In a press release, the company reported that its experimental injectable drug, retatrutide, helped people who were overweight or obese to lose up to 28% of their body weight over 1.5 years compared to people receiving placebo. That’s on par with weight loss associated with bariatric surgery, says Kenneth Custer, executive vice president at Lilly and president of cardiometabolic health.The results add to previous findings on retatrutide among people with obesity and diabetes, which showed that the drug helped them lose 16.8% of their body weight compared to those taking placebo, in addition to lowering their blood sugar.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at TIME — Top.
Discussion
0 commentsMore from TIME — Top
